Physician profile
Ashish Khot
NPI 1871822619
$88,440.49
in general payments reported to CMS, 2019-2025
72 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,370 · 2020: $1,060 · 2021: $992 · 2022: $9,652 · 2023: $38K · 2024: $23K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Travel and Lodging: $6,201 · Food and Beverage: $5,661 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,590 · Honoraria: $2,960 · Consulting Fee: $1,455 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,307.50 |
| Travel and Lodging | $6,201.06 |
| Food and Beverage | $5,660.90 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,590.00 |
| Honoraria | $2,960.00 |
| Consulting Fee | $1,455.00 |
| Education | $191.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $33,056.64 | 2020-2025 | Cabometyx |
| Astellas Pharma US INC | $18,785.95 | 2019-2025 | Padcev, Xtandi |
| Pfizer INC. | $12,650.85 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $10,932.19 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $4,009.03 | 2020-2023 | Padcev |
| Incyte Corporation | $1,671.48 | 2019-2024 | Jakafi |
| Novartis Pharmaceuticals Corporation | $763.77 | 2019-2025 | |
| Janssen Biotech, INC. | $717.66 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| Genzyme Corporation | $642.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $398.39 | 2019-2025 | Tagrisso, Imfinzi |
| Amgen INC. | $295.03 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $264.39 | 2019-2024 | Opdivo |
| Genentech USA, INC. | $252.49 | 2019-2024 | Polivy, Columvi, Lunsumio |
| Daiichi Sankyo INC. | $211.71 | 2019-2025 | Enhertu, Datroway, Vanflyta |
| Bayer Healthcare Pharmaceuticals INC. | $199.08 | 2019-2025 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Khot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.